HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis

Tissue Antigens

Volumn 74, Issue 1, 2009, Pages 17-21

  Stankovich, J ^a   Butzkueven, H ^b,c   Marriott, M ^b,c   Chapman, C ^c   Tubridy, N ^c,d   Tait, B D ^e   Varney, M D ^e   Taylor, B V ^a   Foote, S J ^a   Kilpatrick, T J ^b,c   Rubio, Justin P ^b   Booth, D R ^f   Broadley, S ^f   Greer, J M ^f   Grifffiths, L R ^f   Heard, R N ^f   Lechner Scott, J ^f   Pender, M J ^f   Scott, R J ^f   Stewart, G J ^f  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d St Vincent's Healthcare Group   (Ireland)

^e AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^f The Australian Red Cross Blood Service ^*

Author keywords

Australians; Clinical course; Human leucocyte antigen DRB1; Multiple sclerosis; Susceptibility

Indexed keywords

HLA DR ANTIGEN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; AUSTRALIA; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; GENE LOCUS; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AUSTRALIA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 66949137791     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01262.x     Document Type: Article

References (26)

1. Chataway J, Mander A, Robertson N et al. Multiple sclerosis in sibling pairs: an analysis of 250 families. J Neurol Neurosurg Psychiatry 2001 : 71 : 757 61.
2. Oturai AB, Ryder LP, Fredrikson S et al. Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Mult Scler 2004 : 10 : 5 8. (Pubitemid 38100520)
3. Hensiek AE, Seaman SR, Barcellos LF et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007 : 68 : 376 83.
4. Gregory SG, Schmidt S, Seth P et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007 : 39 : 1083 91.
5. Lundmark F, Duvefelt K, Hillert J. Genetic association analysis of the interleukin 7 gene (IL7) in multiple sclerosis. J Neuroimmunol 2007 : 192 : 171 3.
6. Booth DR, Arthur AT, Teutsch SM et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med 2005 : 83 : 822 30.
7. McKay FC, Swain LI, Schibeci SD et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes Immun 2008 : 9 : 1 6. (Pubitemid 351150028)
8. Madigand M, Oger JJ, Fauchet R et al. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 1982 : 53 : 519 29.
9. Francis DA, Batchelor JR, McDonald WI et al. Multiple sclerosis in north-east Scotland. An association with HLA-DQw1. Brain 1987 : 110 : 181 96.
10. Olerup O, Hillert J, Fredrikson S et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A 1989 : 86 : 7113 7.
11. Weinshenker BG, Santrach P, Bissonet AS et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998 : 51 : 742 7.
12. McDonnell GV, Mawhinney H, Graham CA et al. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 1999 : 165 : 77 83. (Pubitemid 29298086)
13. Masterman T, Ligers A, Olsson T et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000 : 48 : 211 9.
14. Marrosu MG, Cocco E, Costa G et al. Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. J Neurol 2006 : 253 : 208 13.
15. Smestad C, Brynedal B, Jonasdottir G et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007 : 14 : 835 40.
16. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 : 13 : 227 31.
17. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 : 50 : 121 7.
18. Paty DW, Oger JJ, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988 : 38 : 180 5.
19. Kimura A, Sasasuki T. Eleventh International Histocompatibility Workshop Reference Protocol for the HLA DNA-typing Technique. In : Tsuji K, Aizawa M, Sasazuki T, eds. Oxford University Press : Oxford, New York, Tokyo 1991 486 97.
20. Kotsch K, Wehling J, Blasczyk R. Sequencing of HLA class II genes based on the conserved diversity of the non-coding regions: sequencing based typing of HLA-DRB genes. Tissue Antigens 1999 : 53 : 486 97.
21. De Luca GC, Ramagopalan BM, Herrera BM et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007 : 104 : 20896 901.
22. Dyment DA, Herrera BM, Cader MZ et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005 : 14 : 2019 26.
23. Barcellos LF, Sawcer S, Ramsay PP et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006 : 15 : 2813 24.
24. Marrosu MG, Murru MR, Costa G et al. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 1998 : 7 : 1235 7.
25. Modin H, Olsson W, Hillert J et al. Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. Am J Hum Genet 2004 : 74 : 1321 2.
26. Roxburgh RH, Seaman SR, Masterman T et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005 : 64 : 1144 51.